Application | Comment | Organism |
---|---|---|
pharmacology | in vitro analysis of apoptotic mechanism of isorhamnetin in Lewis lung cancer (LLC) cells, in vivo anti-cancer efficacy | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
benzyloxycarbonyl-LEHD-fluoromethylketone | i.e. z-LEHD-FMK, specific caspase-9 inhibitor, concentration of 50 microM, inhibitor effect on isorhamnetin-induced apoptosis, cells exposed to DMSO or 40 microM isorhamnetin for 48 h | Mus musculus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | Mus musculus | mitochondria-dependent caspase activation for mediation of isorhamnetin-induced apoptosis | ? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | Q9R0T0 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
Lewis lung carcinoma cell | isolated from 5-week-old female C57BL/6 mice, intraperitoneal injection of isorhamnetin (0.1 or 0.5 mg/kg) four days after tumor inoculation | Mus musculus | - |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
additional information | - |
apoptotic mechanism of the flavanoid isorhamnetin, isorhamnetin induces mitochondria-dependent caspase activation cascade, caspase inhibitors block isorhamnetin-induced apoptosis, increased cleavage of caspase-9 shown by Western blot analyses of isorhamnetin-treated cells, cytotoxicity assay, TUNEL assay, DNA fragmentation assay, measurement of mitochondrial membrane potential | Mus musculus |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | mitochondria-dependent caspase activation for mediation of isorhamnetin-induced apoptosis | Mus musculus | ? | - |
? |